|
Volumn 3, Issue 6, 2004, Pages 418-420
|
Mortality studies in SLE: How far can we improve survival of patients with SLE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
GAMMA INTERFERON ANTIBODY;
INFLUENZA VACCINE;
INTERLEUKIN 10 ANTIBODY;
PNEUMOCOCCUS VACCINE;
TUMOR NECROSIS FACTOR ANTIBODY;
AGE DISTRIBUTION;
ATHEROSCLEROSIS;
BLOOD PRESSURE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CAUSE OF DEATH;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG SAFETY;
EDITORIAL;
HUMAN;
HYPERGLYCEMIA;
INCIDENCE;
INFECTION;
ISCHEMIC HEART DISEASE;
MORBIDITY;
MORTALITY;
PATHOGENESIS;
PREVALENCE;
PROGNOSIS;
QUALITY OF LIFE;
RISK ASSESSMENT;
RISK FACTOR;
SURVIVAL RATE;
SYSTEMIC LUPUS ERYTHEMATOSUS;
VACCINATION;
COHORT STUDIES;
HUMANS;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
SURVIVAL RATE;
WOMEN;
|
EID: 4444303963
PISSN: 15689972
EISSN: None
Source Type: Journal
DOI: 10.1016/j.autrev.2004.07.003 Document Type: Editorial |
Times cited : (25)
|
References (10)
|